CN1939525A - 制备抗病毒口服液的新工艺 - Google Patents
制备抗病毒口服液的新工艺 Download PDFInfo
- Publication number
- CN1939525A CN1939525A CN 200610122442 CN200610122442A CN1939525A CN 1939525 A CN1939525 A CN 1939525A CN 200610122442 CN200610122442 CN 200610122442 CN 200610122442 A CN200610122442 A CN 200610122442A CN 1939525 A CN1939525 A CN 1939525A
- Authority
- CN
- China
- Prior art keywords
- volatile oil
- cyclodextrin
- emulsion
- liquid
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 89
- 230000000840 anti-viral effect Effects 0.000 title abstract description 18
- 238000004519 manufacturing process Methods 0.000 title abstract description 3
- 239000000341 volatile oil Substances 0.000 claims abstract description 74
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 58
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 33
- 238000002156 mixing Methods 0.000 claims abstract description 21
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 238000000926 separation method Methods 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims description 56
- 230000002155 anti-virotic effect Effects 0.000 claims description 36
- 238000002360 preparation method Methods 0.000 claims description 27
- 239000000839 emulsion Substances 0.000 claims description 26
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 24
- 238000005516 engineering process Methods 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 23
- 239000012141 concentrate Substances 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 11
- WHGYBXFWUBPSRW-UHFFFAOYSA-N Cycloheptaamylose Natural products O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO WHGYBXFWUBPSRW-UHFFFAOYSA-N 0.000 claims description 10
- 238000005352 clarification Methods 0.000 claims description 10
- 230000018044 dehydration Effects 0.000 claims description 9
- 238000006297 dehydration reaction Methods 0.000 claims description 9
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 9
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 8
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 7
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 7
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 6
- 241001597008 Nomeidae Species 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 5
- 238000000265 homogenisation Methods 0.000 claims description 5
- 239000010231 banlangen Substances 0.000 claims description 4
- 239000001116 FEMA 4028 Substances 0.000 claims description 3
- 229960004853 betadex Drugs 0.000 claims description 3
- 238000005304 joining Methods 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 2
- 238000004821 distillation Methods 0.000 claims description 2
- 238000002386 leaching Methods 0.000 claims description 2
- 239000012567 medical material Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 abstract description 10
- 239000000126 substance Substances 0.000 abstract description 2
- GGHMUJBZYLPWFD-UHFFFAOYSA-N patchoulialcohol Chemical compound C1CC2(C)C3(O)CCC(C)C2CC1C3(C)C GGHMUJBZYLPWFD-UHFFFAOYSA-N 0.000 description 32
- 239000000047 product Substances 0.000 description 17
- 230000001954 sterilising effect Effects 0.000 description 17
- 238000004659 sterilization and disinfection Methods 0.000 description 17
- GGHMUJBZYLPWFD-MYYUVRNCSA-N Patchouli alcohol Natural products O[C@@]12C(C)(C)[C@H]3C[C@H]([C@H](C)CC1)[C@]2(C)CC3 GGHMUJBZYLPWFD-MYYUVRNCSA-N 0.000 description 16
- 125000003118 aryl group Chemical group 0.000 description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 238000004817 gas chromatography Methods 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000498 ball milling Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- -1 dimethyl cycloheptaamylose Chemical compound 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 238000010813 internal standard method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
20051201 | 20051202 | 20051203 | |
0个月 | 39μg/支 | 34μg/支 | 18μg/支 |
1个月 | 34μg/支 | 30μg/支 | 10μg/支 |
2个月 | 32μg/支 | 28μg/支 | 5μg/支 |
3个月 | 25μg/支 | 21μg/支 | 0μg/支 |
6个月 | 21μg/支 | 18μg/支 | 0μg/支 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610122442A CN1939525B (zh) | 2006-09-27 | 2006-09-27 | 制备抗病毒口服液的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610122442A CN1939525B (zh) | 2006-09-27 | 2006-09-27 | 制备抗病毒口服液的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1939525A true CN1939525A (zh) | 2007-04-04 |
CN1939525B CN1939525B (zh) | 2010-05-12 |
Family
ID=37958228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200610122442A Active CN1939525B (zh) | 2006-09-27 | 2006-09-27 | 制备抗病毒口服液的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1939525B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102000236A (zh) * | 2010-11-23 | 2011-04-06 | 康美药业股份有限公司 | 制备挥发油包合物的方法及其应用 |
CN102940856A (zh) * | 2012-12-12 | 2013-02-27 | 杭州老桐君制药有限公司 | 一种抗病毒口服液制备方法及其产品 |
CN103623345A (zh) * | 2013-11-27 | 2014-03-12 | 郑州大明药物科技有限公司 | 抗病毒口服液的制备方法 |
CN109432361A (zh) * | 2018-12-21 | 2019-03-08 | 安徽东盛友邦制药有限公司 | 一种提高抗病毒口服液有效成分的制备方法 |
CN109498563A (zh) * | 2018-12-21 | 2019-03-22 | 安徽东盛友邦制药有限公司 | 一种抗病毒口服液的制备工艺方法 |
CN113533603A (zh) * | 2020-04-21 | 2021-10-22 | 中国科学院上海药物研究所 | 广藿香油的质量检测方法、其包合物、干混悬剂及其用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1256975C (zh) * | 2001-12-20 | 2006-05-24 | 珠海金沙(湖南)制药有限公司 | 一种抗病毒复方中药及其制备方法 |
-
2006
- 2006-09-27 CN CN200610122442A patent/CN1939525B/zh active Active
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102000236A (zh) * | 2010-11-23 | 2011-04-06 | 康美药业股份有限公司 | 制备挥发油包合物的方法及其应用 |
CN102000236B (zh) * | 2010-11-23 | 2012-05-23 | 康美药业股份有限公司 | 制备挥发油包合物的方法及其应用 |
CN102940856A (zh) * | 2012-12-12 | 2013-02-27 | 杭州老桐君制药有限公司 | 一种抗病毒口服液制备方法及其产品 |
CN103623345A (zh) * | 2013-11-27 | 2014-03-12 | 郑州大明药物科技有限公司 | 抗病毒口服液的制备方法 |
CN103623345B (zh) * | 2013-11-27 | 2015-11-11 | 郑州大明药物科技有限公司 | 抗病毒口服液的制备方法 |
CN109432361A (zh) * | 2018-12-21 | 2019-03-08 | 安徽东盛友邦制药有限公司 | 一种提高抗病毒口服液有效成分的制备方法 |
CN109498563A (zh) * | 2018-12-21 | 2019-03-22 | 安徽东盛友邦制药有限公司 | 一种抗病毒口服液的制备工艺方法 |
CN113533603A (zh) * | 2020-04-21 | 2021-10-22 | 中国科学院上海药物研究所 | 广藿香油的质量检测方法、其包合物、干混悬剂及其用途 |
Also Published As
Publication number | Publication date |
---|---|
CN1939525B (zh) | 2010-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1939525A (zh) | 制备抗病毒口服液的新工艺 | |
CN101062077A (zh) | 一种同时制备甜叶菊总甜菊苷和甜叶菊总黄酮的方法 | |
CN1785255A (zh) | 一种中药制剂的质量控制方法 | |
CN1762465A (zh) | 滴通鼻炎凝胶及其制备方法、质量控制技术 | |
CN1310029C (zh) | 良附滴丸的质量控制方法 | |
CN1570133A (zh) | 一种制备人参皂甙Compound-K的方法 | |
CN1895296A (zh) | 一种检测灵芝产品口服制剂质量的方法 | |
CN1891284A (zh) | 一种中药组合物及其制备方法和质量控制方法 | |
CN1857551A (zh) | 一种中药制剂的质量控制方法 | |
CN1907436A (zh) | 一种治疗小儿厌食的药物组合物及其制备工艺 | |
KR101192117B1 (ko) | 통기펠렛배양법을 이용한 발효인삼 또는 발효홍삼 제조방법 | |
CN1907340A (zh) | 一种肾石通制剂的质量检测控制方法 | |
CN105770375A (zh) | 一种伊贝母提取物的制备方法和用途 | |
CN1857406A (zh) | 一种中药制剂的质量控制方法 | |
CN1259099C (zh) | 一种治疗胃脘痛的中成药良附滴丸及其制备工艺 | |
CN1283289C (zh) | 一种治疗眩晕病中药制剂及制备方法 | |
CN101045077A (zh) | 一种胡芦巴口服固体制剂的制备方法及其应用 | |
CN1309373C (zh) | 一种治疗癌症的颗粒剂及其质量控制方法 | |
CN1899552A (zh) | 无糖型橘红痰咳口服液 | |
CN1943633A (zh) | 蒲地蓝消炎颗粒的制备方法及该方法制备的蒲地蓝消炎颗粒 | |
CN1695712A (zh) | 一种止咳化痰平喘的药物及其生产制备方法 | |
CN1850132A (zh) | 一种百蕊颗粒及其制备方法 | |
CN105037311A (zh) | 一种芹菜素在线二维复合液相提取纯化方法 | |
CN1634431A (zh) | 一种治疗上呼吸道感染的银黄滴丸 | |
CN1042656A (zh) | “鸡乐”的制造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20070404 Assignee: Guangzhou Kaide Finance Leasing Co.,Ltd. Assignor: GUANGZHOU XIANGXUE PHARMACEUTICAL Co.,Ltd. Contract record no.: X2020440000123 Denomination of invention: Preparation of antiviral oral liquid Granted publication date: 20100512 License type: Exclusive License Record date: 20200915 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation of antiviral oral liquid Effective date of registration: 20200916 Granted publication date: 20100512 Pledgee: Guangzhou Kaide Finance Leasing Co.,Ltd. Pledgor: GUANGZHOU XIANGXUE PHARMACEUTICAL Co.,Ltd. Registration number: Y2020440000277 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20201020 Granted publication date: 20100512 Pledgee: Guangzhou Kaide Finance Leasing Co.,Ltd. Pledgor: GUANGZHOU XIANGXUE PHARMACEUTICAL Co.,Ltd. Registration number: Y2020440000277 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Guangzhou Kaide Finance Leasing Co.,Ltd. Assignor: GUANGZHOU XIANGXUE PHARMACEUTICAL Co.,Ltd. Contract record no.: X2020440000123 Date of cancellation: 20201022 |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20070404 Assignee: Guangzhou Kaide Finance Leasing Co.,Ltd. Assignor: GUANGZHOU XIANGXUE PHARMACEUTICAL Co.,Ltd. Contract record no.: X2020440000133 Denomination of invention: Preparation of antiviral oral liquid Granted publication date: 20100512 License type: Exclusive License Record date: 20201027 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation of antiviral oral liquid Effective date of registration: 20201028 Granted publication date: 20100512 Pledgee: Guangzhou Kaide Finance Leasing Co.,Ltd. Pledgor: GUANGZHOU XIANGXUE PHARMACEUTICAL Co.,Ltd. Registration number: Y2020440000343 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20231218 Granted publication date: 20100512 Pledgee: Guangzhou Kaide Finance Leasing Co.,Ltd. Pledgor: GUANGZHOU XIANGXUE PHARMACEUTICAL Co.,Ltd. Registration number: Y2020440000343 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |